News
Oncology Therapy at the End of Life: Have We Missed the Mark?
In a study published today in JAMA Oncology, researchers at Yale Cancer Center in collaboration with researchers from Flatiron Health, Inc., revealed that despite recommendations, aggressive cancer care at the end-of-life persists and there has been a substantial transition from the use of chemotherapy to immunotherapy.